Indiana Biosciences Research Institute

The Indiana Biosciences Research Institute (IBRI) is an American nonprofit translational research organization headquartered in Indianapolis, Indiana, United States[1] within the 16 Tech Innovation District.[2] The IBRI is the nation's first industry-led collaborative life sciences research institute.[3] Its primary focus is on better understanding the pathogenesis of type 1 and type 2 diabetes to translate this knowledge into novel therapies,[4] while also expanding into other metabolic diseases that share common systems and pathways.[5]

Indiana Biosciences Research Institute
FormationMay 1, 2013 (2013-05-01)
TypeResearch Institute
HeadquartersIndianapolis, Indiana, U.S.
Region served
Indiana
Staff
100
Websitehttp://indianabiosciences.org

History

In 2012, pharmaceutical executive John C. Lechleiter from Eli Lilly & Company initially proposed the IBRI.[6][7] In 2013, Indiana governor Mike Pence announced the formation of the IBRI.[8] Pence later worked with life sciences leaders to secure $25 million in startup funds from the state.[9]

In 2015, the IBRI hired David Broecker as CEO.[10] In late 2015, the Indianapolis City-County Council approved $75 million to build a technology park called 16 Tech.[11] In 2016, the IBRI hired Rainer Fischer as Chief Scientific Officer.[12][13] In 2017, Governor Eric Holcomb reaffirmed the commitment made by his predecessor Mike Pence.[14][15][16]

Leadership

Appointees to the IBRI’s Board of Directors include:

References
  1. Rudavsky, Shari (February 24, 2016). "New biosciences institute gets $100M". Indianapolis Star. Retrieved June 22, 2017.
  2. Orr, Susan (March 16, 2022). "16 Tech Promotes Emily Krueger to Chief Executive". Indianapolis Business Journal. Retrieved August 15, 2022.
  3. "Bioscience Research Institute Creates a 'Petri Dish' for Innovation". Crain Communications. June 30, 2016. Retrieved June 22, 2017.
  4. "IBRI Welcomes New Leader". Inside INdiana Business. Retrieved 2022-08-16.
  5. "How We Study Alzheimer's and Potential Treatments". Indiana University Precision Health Initiative, Healthcare Triage. Retrieved 2022-08-16.
  6. Lechleiter, John (March 31, 2015). "From hunting to farming, medicines development takes a big leap forward". Forbes. Retrieved June 22, 2017.
  7. Pogorelc, Deanna (May 30, 2013). "Eli Lilly, Roche, device makers collaborate on new public-private research institute in Indiana". MedCity News. Retrieved June 22, 2017.
  8. Pence, Mike (May 30, 2013). "Governor Pence Announces Indiana Biosciences Research Institute". YouTube. Retrieved June 22, 2017.
  9. Nather, David (July 16, 2016). "With Pence pick, Trump just made women's health a top-tier election issue". PBS. Retrieved June 22, 2017.
  10. Swiatek, Jeff (May 19, 2015). "New CEO of bioscience institute looks to hire researchers, raise millions". Indianapolis Star. Retrieved June 22, 2017.
  11. Eason, Brian (November 9, 2015). "City-County Council OKs $75M for Indianapolis tech park". USA Today. Retrieved June 22, 2017.
  12. Ober, Andy (October 4, 2016). "IBRI hires European bioscience giant". Inside INdiana Business. Retrieved June 22, 2017.
  13. Russell, John (April 1, 2017). "FOCUS: Biosciences institute's chief scientific officer aims to foster commercialization". Indianapolis Business Journal. Retrieved June 22, 2017.
  14. Redman, Mary-Rachel (January 16, 2017). "Roche CEO: IBRI Will Succeed Where Others Have Failed". Inside INdiana Business. Retrieved June 22, 2017.
  15. Lange, Kaitlin (April 21, 2017). "How Gov. Holcomb's priorities fared in the state budget". Indianapolis Star. Retrieved June 22, 2017.
  16. Heinz, Katie (January 5, 2017). "Governor-elect Eric Holcomb unveils 2017 legislative agenda". WRTV. Retrieved June 22, 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.